PubMed HealthSearch

Biomedical subjects

L Judd

Publications and source records attributed to L Judd.

13 recordsLinked to original sources

Application of molecular encapsulation for toxicology studies: toxicokinetics of p-chloro-alpha,alpha,alpha-trifluorotoluene in alpha-cyclodextrin or corn oil vehicles in male F344 rats.

Toxicokinetics of p-chloro-alpha,alpha,alpha-trifluorotoluene (CTFT) after administration as an aqueous alpha-cyclodextrin (alpha-CD) molecular encapsulation suspension (alpha-CD vehicle) or as a corn oil solution (corn oil vehicle) were compared. Male F344 rats were administered intragastrically CTFT in alpha-CD vehicle or corn oil vehicle at dose levels of 10, 50, or 400 mg/kg. Other male F344 rats were administered CTFT intravenously in a 10% Tween 80 aqueous solution. Serial blood samples were taken from a cannulated jugular vein for up to 52 hr after dosing and the CTFT concentrations in whole blood were determined by gas chromatography. The biological elimination half-life of CTFT from the center compartment was not affected by the vehicle used; however, absorption of CTFT from the alpha-CD vehicle was much faster than from the corn oil vehicle. The average absorption half-lives from the alpha-CD vehicle and corn oil vehicle were 17 and 98 min, respectively. Despite the differences in absorption, no statistical difference was observed in the calculated areas under the blood concentration versus time curves (AUC) obtained from rats dosed with either vehicle. Dose proportionality for CTFT was established up to 400 mg/kg and bioavailability was shown to be complete for both vehicles.

Administration, Oral

Human growth hormone releasing factor infusion effects on plasma growth hormone in affective disorder patients and normal controls.

In a preliminary, prospective pilot study, five patients with major depressive disorder and eleven age and sex matched normal controls received intravenous human growth hormone releasing factor (hGRF) (1 microgram/kg in 5 cc of normal saline infused over five minutes) and placebo. Thirty minutes after insertion of the catheter, blood was sampled every 15 minutes for thirty minutes prior to and for 2 hours subsequent to intravenous infusion of hGRF or placebo. hGRF but not placebo caused significant elevations of plasma growth hormone levels in all subjects. Of interest, the depressed patients had a significantly attenuated rise in plasma growth hormone concentrations when compared with the normal controls. These results must be considered preliminary awaiting replication with a larger subject population.

Adult

Naloxone effects on serum growth hormone and prolactin in man.

Endogenous and exogenous opiate-like compounds have been found to cause increased serum growth hormone and prolactin levels in animals, and, in some cases, humans. Naloxone, a relatively specific narcotic antagonist, decreases serum prolactin and growth hormone levels in animals. Naloxone (20 mg IV) did not significantly alter serum prolactin levels and, minimally but not significantly, increased growth hormone levels in humans to whom it was administered.

Growth Hormone

Differential effects of methylphenidate and d-amphetamine on stereotyped behavior in the rat.

Different equimolar doses of d-amphetamine and methylphenidate were compared for their potency in eliciting stereotyped behavior in rats. Although at lower doses d-amphetamine appeared more effective in causing stereotyped gnawing, repetitive body movements, and sniffing, at higher doses methylphenidate at certain times caused a greater incidence of gnawing than did d-amphetamine. Understanding these differences and comparing related biochemical correlates may lead to a better definition of mechanisms underlying psychostimulant effects.

Animals

Methylphenidate and serum prolactin in man.

Methylphenidate induces psychostimulation and increases cardiovascular parameters, and its psychostimulant effects have been proposed to occur via a dopaminergic mechanism. The effect of methylphenidate on serum prolactin was utilized as a method of evaluating methylphenidate's central dopamimergic effects. Methylphenidate was not found to exhibit a consistent effect on serum prolactin. Thus, its effect on serum prolactin does not parallel its behavioral activating properties, suggesting that such activation may not involve dopamine. Possibly, norepinephrine or other noncatecholaminergic neurotransmitters are involved in methylphenidate-induced behavioral activation.

Adult

The effect of methylphenidate on serum growth hormone: influence of antipsychotic drugs and diagnosis.

Intravenously administered methylphenidate, 0.5 mg/kg, causes a consistent rise in human serum growth hormone level, with peak values usually occurring 30 minutes after infusion. This rise is attenuated in patients receiving various antipsychotic medications administered on a long-term basis and is decreased in schizophrenic and drug-dependent patients. Methylphenidate causes increases in talkativeness, blood pressure, and pulse that generally parallel increases in serum growth hormone level. However, in contrast to the methylphenidate-induced rise in serum growth hormone level, methylphenidate-induced changes in cardiovascular variables and talkativeness are not altered by antipsychotic medications or diagnostic classification.

Adjustment Disorders

Acupuncture.

Explore the source record for details and available documents.

Acupuncture Therapy